Combogesic Shortage: What Providers and Prescribers Need to Know in 2026

As Combogesic (acetaminophen / ibuprofen) has become an increasingly common prescribing choice for postoperative pain, acute musculoskeletal injuries, and outpatient analgesia, some prescribers are fielding questions from patients who can't fill the prescription at their local pharmacy. This guide is designed for clinicians who want a clear picture of the 2026 availability landscape and practical guidance for managing patients when Combogesic is not readily accessible.

Is Combogesic in an Official Drug Shortage?

As of early 2026, Combogesic does not appear on the FDA drug shortage database or the ASHP shortage list. There is no declared manufacturing or supply disruption. The availability challenges patients and prescribers are experiencing reflect the realities of early commercial distribution for a newer, brand-only product — not a systemic supply chain failure.

Clinical Background: Combogesic's Two Formulations

Prescribers should be aware that Combogesic is available in two distinct FDA-approved formulations with different use settings:

Combogesic tablets (oral): Acetaminophen 325 mg / ibuprofen 97.5 mg per tablet. Dose: 3 tablets every 6 hours, max 12 tablets/day. Indicated for short-term management of mild to moderate acute pain in adults. Prescription-required; retail pharmacy dispensed.

Combogesic IV (intravenous): Acetaminophen 1,000 mg / ibuprofen 300 mg per 100 mL. Dose: 15-minute IV infusion every 6 hours as needed; max 4,000 mg acetaminophen and 1,200 mg ibuprofen/24 hours; up to 5 days. Indicated for adults where IV analgesia is clinically necessary. Hospital/inpatient formulary only. CMS J-code J0138 (effective October 1, 2024).

Why Are Patients Having Trouble Filling Combogesic Prescriptions?

Several structural factors contribute to limited retail pharmacy availability:

No generic competition: Patents extend through approximately 2035, and market exclusivity ran through October 2026. Pharmacies may deprioritize ordering newer brand-only agents with limited prescribing volume.

Formulary gaps: Many PBMs and insurance formularies may place Combogesic on higher tiers or require prior authorization, as it is a newer branded product without a generic reference.

Uneven retail distribution: Many independent and regional pharmacies have not yet added Combogesic to standard inventory. Large chains (CVS, Walgreens, Walmart) are more likely to stock it.

Therapeutic Substitution Options When Combogesic Is Unavailable

The therapeutic rationale for Combogesic is multimodal analgesia combining central (acetaminophen) and peripheral anti-inflammatory (ibuprofen) mechanisms. When substituting, consider maintaining this multimodal approach:

Acetaminophen + ibuprofen OTC separately: Prescribing (or recommending) OTC acetaminophen 500-650 mg and OTC ibuprofen 200-400 mg on alternating or simultaneous schedules can provide comparable coverage at much lower cost. This is common clinical practice and is often cost-effective for acute short-term pain.

Ketorolac (Toradol): Appropriate for moderate to severe acute pain where an opioid-sparing NSAID is needed. Available IV, IM, oral (10 mg tabs), and intranasal (Sprix). FDA-limited to 5 days.

Celecoxib (Celebrex): COX-2 selective NSAID; lower GI bleeding risk; oral formulation; generic available. Appropriate for patients with GI concerns or when ongoing use beyond 5 days is anticipated.

IV alternatives (for Combogesic IV): IV acetaminophen (Ofirmev/generic) + IV ibuprofen (Caldolor) given separately; or IV ketorolac (Toradol) as a standalone NSAID for acute hospital pain management.

Boxed Warnings Prescribers Must Know

Both formulations of Combogesic carry boxed warnings for:

Hepatotoxicity: Acetaminophen doses exceeding 4,000 mg/day from all sources are associated with acute liver failure. Counsel patients to avoid concurrent acetaminophen-containing products (many OTC cold, flu, and sleep medications contain acetaminophen).

Cardiovascular thrombotic events: Ibuprofen increases risk of MI and stroke; risk increases with dose and duration. Combogesic is contraindicated in the setting of CABG surgery.

GI risk: Serious GI bleeding, ulceration, and perforation have been reported with NSAIDs. Risk is elevated in patients with prior GI events, elderly patients, and those on anticoagulants or SSRIs.

How to Help Your Patients Find Combogesic

When patients call back saying they can't fill their Combogesic prescription, the fastest resource to point them toward is medfinder. medfinder contacts pharmacies near the patient's location to check which ones have Combogesic in stock, and texts the results back. It's a fast, low-friction tool that reduces back-and-forth with your office staff. See our provider-specific guide: How to help your patients find Combogesic in stock.

Key Takeaways for Prescribers

Combogesic is not in an official shortage, but retail availability is uneven due to its status as a newer brand-only product.

Consider advising patients to call larger chain pharmacies or use medfinder to locate it.

When substituting, maintain multimodal analgesia by combining a central agent (acetaminophen) with a peripheral NSAID.

Counsel patients on all three boxed warnings: hepatotoxicity, CV thrombotic events, and GI risk.